275 related articles for article (PubMed ID: 35135845)
1. MMD-associated
Bhardwaj A; Banh RS; Zhang W; Sidhu SS; Neel BG
Life Sci Alliance; 2022 May; 5(5):. PubMed ID: 35135845
[TBL] [Abstract][Full Text] [Related]
2. Moyamoya disease patient mutations in the RING domain of RNF213 reduce its ubiquitin ligase activity and enhance NFκB activation and apoptosis in an AAA+ domain-dependent manner.
Takeda M; Tezuka T; Kim M; Choi J; Oichi Y; Kobayashi H; Harada KH; Mizushima T; Taketani S; Koizumi A; Youssefian S
Biochem Biophys Res Commun; 2020 May; 525(3):668-674. PubMed ID: 32139119
[TBL] [Abstract][Full Text] [Related]
3. A new horizon of moyamoya disease and associated health risks explored through RNF213.
Koizumi A; Kobayashi H; Hitomi T; Harada KH; Habu T; Youssefian S
Environ Health Prev Med; 2016 Mar; 21(2):55-70. PubMed ID: 26662949
[TBL] [Abstract][Full Text] [Related]
4. Importance of RNF213 polymorphism on clinical features and long-term outcome in moyamoya disease.
Kim EH; Yum MS; Ra YS; Park JB; Ahn JS; Kim GH; Goo HW; Ko TS; Yoo HW
J Neurosurg; 2016 May; 124(5):1221-7. PubMed ID: 26430847
[TBL] [Abstract][Full Text] [Related]
5. Moyamoya disease factor RNF213 is a giant E3 ligase with a dynein-like core and a distinct ubiquitin-transfer mechanism.
Ahel J; Lehner A; Vogel A; Schleiffer A; Meinhart A; Haselbach D; Clausen T
Elife; 2020 Jun; 9():. PubMed ID: 32573437
[TBL] [Abstract][Full Text] [Related]
6. RNF213 as the major susceptibility gene for Chinese patients with moyamoya disease and its clinical relevance.
Zhang Q; Liu Y; Zhang D; Wang R; Zhang Y; Wang S; Yu L; Lu C; Liu F; Zhou J; Zhang X; Zhao J
J Neurosurg; 2017 Apr; 126(4):1106-1113. PubMed ID: 27128593
[TBL] [Abstract][Full Text] [Related]
7. Rare variants of RNF213 and moyamoya/non-moyamoya intracranial artery stenosis/occlusion disease risk: a meta-analysis and systematic review.
Liao X; Deng J; Dai W; Zhang T; Yan J
Environ Health Prev Med; 2017 Nov; 22(1):75. PubMed ID: 29165161
[TBL] [Abstract][Full Text] [Related]
8. RNF213 p.R4810K Polymorphism and the Risk of Moyamoya Disease, Intracranial Major Artery Stenosis/Occlusion, and Quasi-Moyamoya Disease: A Meta-Analysis.
Wang Y; Mambiya M; Li Q; Yang L; Jia H; Han Y; Liu W
J Stroke Cerebrovasc Dis; 2018 Aug; 27(8):2259-2270. PubMed ID: 29752070
[TBL] [Abstract][Full Text] [Related]
9. The Role of RNF213 4810G>A and 4950G>A Variants in Patients with Moyamoya Disease in Korea.
Park YS; An HJ; Kim JO; Kim WS; Han IB; Kim OJ; Kim NK; Kim DS
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29160859
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and Functional Characterization of RNF213 (Mysterin) R4810K, a Susceptibility Mutation of Moyamoya Disease, in Angiogenesis In Vitro and In Vivo.
Kobayashi H; Matsuda Y; Hitomi T; Okuda H; Shioi H; Matsuda T; Imai H; Sone M; Taura D; Harada KH; Habu T; Takagi Y; Miyamoto S; Koizumi A
J Am Heart Assoc; 2015 Jun; 4(7):. PubMed ID: 26126547
[TBL] [Abstract][Full Text] [Related]
11. In silico explanation for the causalities of deleterious RNF213 SNPs in Moyamoya disease and insulin resistance.
Sarkar P; Thirumurugan K
Comput Biol Chem; 2021 Jun; 92():107488. PubMed ID: 33930741
[TBL] [Abstract][Full Text] [Related]
12. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development.
Liu W; Morito D; Takashima S; Mineharu Y; Kobayashi H; Hitomi T; Hashikata H; Matsuura N; Yamazaki S; Toyoda A; Kikuta K; Takagi Y; Harada KH; Fujiyama A; Herzig R; Krischek B; Zou L; Kim JE; Kitakaze M; Miyamoto S; Nagata K; Hashimoto N; Koizumi A
PLoS One; 2011; 6(7):e22542. PubMed ID: 21799892
[TBL] [Abstract][Full Text] [Related]
13. Genetic analysis of
Tashiro R; Fujimura M; Sakata H; Endo H; Tomata Y; Sato-Maeda M; Niizuma K; Tominaga T
Neurol Res; 2019 Sep; 41(9):811-816. PubMed ID: 31064275
[No Abstract] [Full Text] [Related]
14. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene.
Kamada F; Aoki Y; Narisawa A; Abe Y; Komatsuzaki S; Kikuchi A; Kanno J; Niihori T; Ono M; Ishii N; Owada Y; Fujimura M; Mashimo Y; Suzuki Y; Hata A; Tsuchiya S; Tominaga T; Matsubara Y; Kure S
J Hum Genet; 2011 Jan; 56(1):34-40. PubMed ID: 21048783
[TBL] [Abstract][Full Text] [Related]
15. Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population.
Wu Z; Jiang H; Zhang L; Xu X; Zhang X; Kang Z; Song D; Zhang J; Guan M; Gu Y
PLoS One; 2012; 7(10):e48179. PubMed ID: 23110205
[TBL] [Abstract][Full Text] [Related]
16. Role of the
Kim HJ; Choi EH; Chung JW; Kim JH; Kim YS; Seo WK; Kim GM; Bang OY
J Am Heart Assoc; 2021 Jan; 10(1):e017660. PubMed ID: 33356381
[TBL] [Abstract][Full Text] [Related]
17. Impacts and interactions of PDGFRB, MMP-3, TIMP-2, and RNF213 polymorphisms on the risk of Moyamoya disease in Han Chinese human subjects.
Wang X; Zhang Z; Liu W; Xiong Y; Sun W; Huang X; Jiang Y; Ni G; Sun W; Zhou L; Wu L; Zhu W; Li H; Liu X; Xu G
Gene; 2013 Sep; 526(2):437-42. PubMed ID: 23769926
[TBL] [Abstract][Full Text] [Related]
18. RNF213 rs112735431 polymorphism in intracranial artery steno-occlusive disease and moyamoya disease in Koreans.
Park MG; Shin JH; Lee SW; Park HR; Park KP
J Neurol Sci; 2017 Apr; 375():331-334. PubMed ID: 28320162
[TBL] [Abstract][Full Text] [Related]
19.
Ok T; Jung YH; Kim J; Park SK; Park G; Lee S; Lee KY
J Am Heart Assoc; 2022 Aug; 11(15):e025676. PubMed ID: 35876407
[TBL] [Abstract][Full Text] [Related]
20. Temporal profile of magnetic resonance angiography and decreased ratio of regulatory T cells after immunological adjuvant administration to mice lacking RNF213, a susceptibility gene for moyamoya disease.
Kanoke A; Fujimura M; Niizuma K; Fujimura T; Kakizaki A; Ito A; Sakata H; Sato-Maeda M; Kure S; Tominaga T
Brain Res; 2016 Jul; 1642():1-9. PubMed ID: 26972532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
